Cirbloc M Hyo (--) + (--) - Emulsion for injection

Authorised

- Mycoplasma hyopneumoniae, strain 2940, Inactivated
- Porcine circovirus type 2d, ORF2 capsid protein

Product identification

Medicine name:
Cirbloc M Hyo (--) + (--) - Emulsion for injection

Active substance:
Mycoplasma hyopneumoniae, strain 2940, Inactivated
Porcine circovirus type 2d, ORF2 capsid protein

Target species:
Pig

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Mycoplasma hyopneumoniae, strain 2940, Inactivated
Presentation_strength:184 AU Reference:HSE Index:0
Porcine circovirus type 2d, ORF2 capsid protein

Presentation_strength:19.6 µg Reference:HSE Index:1

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Pig**
  - All relevant tissues. 0 day zero day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AL08

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:LDP, Package_size:1 bottle, Content:500 ml
Packaging:LDP, Package_size:10 bottles, Content:100 ml
Packaging:LDP, Package_size:6 bottles, Content:250 ml
Packaging:LDP, Package_size:1 bottle, Content:250 ml
Packaging:LDP, Package_size:10 bottle, Content:50 ml
Packaging:LDP, Package_size:1 bottle, Content:100 ml
Packaging:LDP, Package_size:1 bottle, Content:50 ml
Packaging:LDP, Package_size:6 bottles, Content:500 ml
Packaging:LDP, Package_size:48 bottles, Content:100 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - known active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:
CEVA-Phylaxia Zrt.

Marketing authorisation date:
24/10/2024

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
24/10/2024

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 6/11/2024

Download

ema-puar-v6131-cirblocmhyo-initial-en.pdf